On Tuesday, Vertex Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The top-performing stocks tend to have a 95 or better grade as they launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Vertex Pharmaceuticals is currently forming a second consecutive cup without handle, sometimes called a base-on-base, with a 325.29 entry. See if the stock can break out in volume at least 40% higher than normal, which it has not yet shown it can do.
Looking For The Best Stocks To Buy And Watch? Try These Exclusive Lists
The stock sports a 96 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 96% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q4, the company posted 25% earnings-per-share growth. Sales growth fell to 11%, down from 18% in the prior quarter.
Vertex Pharmaceuticals holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the No. 1-ranked stock within the group.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
